Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

39.60
-0.2100-0.53%
Post-market: 39.51-0.0900-0.23%18:26 EDT
Volume:5.65M
Turnover:224.82M
Market Cap:46.13B
PE:66
High:40.28
Open:40.20
Low:39.22
Close:39.81
52wk High:40.79
52wk Low:18.83
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.98
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.95
PE(LYR):32.73

Loading ...

Press Release: TAPI (Technology & API Services) Names Serge Rogasik CEO to Lead Next Chapter of Growth and Competitiveness

Dow Jones
·
2 hours ago

NYSE Order Imbalance 18799.0 Shares on Buy Side

THOMSON REUTERS
·
Yesterday

Teva Reports FDA Approval for Degevma

MT Newswires Live
·
Sep 29

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

TIPRANKS
·
Sep 29

Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says

MT Newswires Live
·
Sep 28

J.P. Morgan Sticks to Their Buy Rating for Teva (TEVA)

TIPRANKS
·
Sep 25

NYSE Order Imbalance 23191.0 Shares on Buy Side

THOMSON REUTERS
·
Sep 25

Teva Releases Q3 2026 Aide Memoire

THOMSON REUTERS
·
Sep 24

Teva Enters Acceleration Phase of Transformation Supported by Multi-Year Launch Cycle, Oppenheimer Says

MT Newswires Live
·
Sep 24

Teva Pharmaceuticals Price Target Announced at $50.00/Share by Oppenheimer

Dow Jones
·
Sep 23

Top Teva Insider Makes Massive Multi-Million Dollar Stock Move

TIPRANKS
·
Sep 23

NYSE Order Imbalance 52798.0 Shares on Buy Side

THOMSON REUTERS
·
Sep 22

Teva presents new new real-world data on uzedy at Psych Congress

TIPRANKS
·
Sep 19

Teva Highlights New Real-World Data Showing Uzedy® (Risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

THOMSON REUTERS
·
Sep 19

Teva Pharmaceutical Announces New Senior Notes Offering

TIPRANKS
·
Sep 17

Movement Alert|Teva Pharmaceutical Rises 5.07% in Regular Trading, Ordinary Shares Begin Direct Trading on NYSE

Market Focus
·
Sep 15

Teva Pharmaceutical Begins Direct Trading of Shares on NYSE

MT Newswires Live
·
Sep 14

Teva Pharmaceutical Announces Major Senior Notes Financing

TIPRANKS
·
Sep 12

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

GlobeNewswire
·
Sep 10

Teva Pharmaceuticals Price Target Announced at $45.00/Share by Leerink Partners

Dow Jones
·
Sep 09